[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100617400":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":29,"centralContacts":34,"locations":43,"responsibleParty":60,"collaborators":63,"id":68,"slug":69,"hasResults":70,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":74,"eligibilityCriteria":75,"healthyVolunteers":70,"sex":76,"minAge":77,"maxAge":78,"enrollmentInfo":79,"targetDuration":25,"studyType":82,"phases":83,"briefSummary":85,"conditions":86,"keywords":88,"overallStatus":46,"whyStopped":25,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":98,"completionDateStruct":99,"leadSponsor":101,"locationsCount":102},{"fullName":5,"class":6},"Glostrup University Hospital, Copenhagen","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Placebo","PLACEBO_COMPARATOR","Placebo capsules",[13],"Dietary Supplement: Placebo",{"label":15,"type":16,"description":17,"interventionNames":18},"Indole-3-propionic acid (IPA)","EXPERIMENTAL","IPA capsules",[19],"Dietary Supplement: Indole-3-propionic acid (IPA)",[21,26],{"type":22,"name":9,"description":23,"armGroupLabels":24,"otherNames":25},"DIETARY_SUPPLEMENT","Two capsules are taken every morning and two capsules are taken every evening for 27 consecutive months. Placebo capsules are taken orally.",[9],null,{"type":22,"name":15,"description":27,"armGroupLabels":28,"otherNames":25},"Two capsules are taken every morning and two capsules are taken every evening for 27 consecutive months. Active capsules are taken orally and contain 250 mg of IPA each resulting in a total daily dose of 1000 mg of IPA.",[15],[30],{"name":31,"affiliation":32,"role":33},"Jette Lautrup Frederiksen, MD, dr.med, professor","Copenhagen University Hospital, Rigshospitalet-Glostrup","PRINCIPAL_INVESTIGATOR",[35,39],{"name":31,"role":36,"phone":37,"phoneExt":25,"email":38},"CONTACT","+4538633041","jette.lautrup.battistini@regionh.dk",{"name":40,"role":36,"phone":41,"phoneExt":25,"email":42},"Moschoula Passali, MSc, PhD","+45 38633467","moschoula.passali@regionh.dk",[44],{"facility":45,"status":46,"city":47,"state":25,"zip":48,"country":49,"countryCode":50,"cosmosGeoPoint":51,"geoPoint":56,"contacts":57},"Glostrup Hospital","RECRUITING","Glostrup Municipality","2600","Denmark","DK",{"type":52,"coordinates":53},"Point",[54,55],12.40377,55.6666,{"lat":55,"lon":54},[58],{"name":31,"role":36,"phone":59,"phoneExt":25,"email":38},"+45386330",{"type":33,"investigatorFullName":61,"investigatorTitle":62,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"Jette Lautrup Frederiksen","MD, dr.med, professor at DMSc",[64,66],{"name":65,"class":6},"University of Copenhagen",{"name":67,"class":6},"University of Southampton","100617400","indole-3-propionic-acid-clinical-trials---multiple-sclerosis-100617400",false,"NCT07318129","Indole-3-PROpionic Acid Clinical Trials - Multiple Sclerosis","Indole-3-PROpionic Acid Clinical Trials - Multiple Sclerosis (iPROACT-MS)","iPROACT-MS","Inclusion Criteria:\n\n* Women and men ≥18 and ≤65 years of age\n* Diagnosed with RRMS according to the 2017 McDonald criteria (or newer updates)\n* Routinely treated and monitored for MS\n* Speak and read Danish\n* Deemed physically and mentally able to participate in this study\n\nExclusion Criteria:\n\n* Active malignancy\n* Diagnosis of Crohn's disease and ulcerative colitis\n* Other comorbidities deemed to be relevant\n* Haematopoietic stem cell transplantation\n* Current or past treatment with non-MS related treatments deemed to be relevant\n* Pregnancy or lactation\n* People with MR contraindications:\n\n  * Severe claustrophobia\n  * Incompatible implants\u002F foreign objects, including implanted pacemakers, heart valve prostheses, prostheses in the middle ear, implanted devices (e.g., insulin pump), metal debris, e.g., metal splinters in the eyes, miscellaneous shunts and catheters, metal clips from operations","ALL","18 Years","65 Years",{"count":80,"type":81},220,"ESTIMATED","INTERVENTIONAL",[84],"NA","This study, iPROACT-MS, is part of the iPROACT group of clinical trials aiming to investigate the effects of oral supplementation with indole-3-propionic acid (IPA) in humans. IPA is naturally produced as a gut bacterial metabolite with the amino acid tryptophan as substrate. The primary aim of iPROACT-MS is to investigate whether patients with relapsing-remitting multiple sclerosis (RRMS) can benefit from supplementation with IPA. The hypothesis is that supplementation with IPA will protect against MS-related disease activity, neurodegeneration and metabolic abnormalities. Secondary, iPROACT-MS aims at elucidating the complex relationships between lifestyle, gut microbial factors, inflammation, oxidative stress, metabolic health, MS disease severity and MS disease activity.",[87],"Relapsing Remitting Multiple Sclerosis (RRMS)",[89,90,91,92,93],"indole-3-propionic acid","multiple sclerosis","gut bacterial metabolite","dietary supplement","gut-brain axis","2026-01-26",{"date":96,"type":97},"2026-01-28","ACTUAL",{"date":94,"type":97},{"date":100,"type":81},"2028-07-15",{"name":5,"class":6},1]